

**Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness**

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Yazdanpanah, Y., J. Perelman, M. A. DiLorenzo, J. Alves, H. Barros, C. Mateus, J. Pereira, et al. 2013. “Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness.” PLoS ONE 8 (12): e84173. doi:10.1371/journal.pone.0084173. http://dx.doi.org/10.1371/journal.pone.0084173. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1371/journal.pone.0084173                                                                                                                                                                                                                                    |
| Citable link     | http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879235                                                                                                                                                                                                                 |
| Terms of Use     | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA                                                                                                                                 |


Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness

Yazdan Yazdanpanah1,2, Julian Perelman3, Madeline A. DiLorenzo4,5, Joana Alves1, Henrique Barros4, Céu Mateus1, João Pereira5, Kamal Mansinho6, Marion Robine8,9, Ji-Eun Park8,9, Eric L. Ross8,9, Elena Losina7,8,10,11,13, Rochelle P. Walensky6,7,8,9,10,11, Farzad Noubary14,15, Kenneth A. Freedberg6,7,8,9,11,12, A. David Paltiel16

1 Hôpital Bichat, Université Paris Diderot, Paris, France, 2 ATIP-Avenir Inserm: “Modélisation, Aide à la Décision, et Coût-Efficacité en Maladies Infectieuses,” Inserm U1137, Université Denis Diderot, Paris, France, 3 Escola Nacional de Saúde Pública, Universidade Nova de Lisboa, Lisbon, Portugal, 4 Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal, 5 Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal, 6 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 7 Harvard Medical School, Boston, Massachusetts, United States of America, 8 Division of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 9 Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 10 Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 11 Harvard Center for AIDS Research, Boston, Massachusetts, United States of America, 12 Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America, 13 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America, 14 The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States of America, 15 Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts, United States of America, 16 Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, United States of America

Abstract

Objective: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the current practice of targeted and on-demand screening.

Design: We used Portuguese national clinical and economic data to conduct a model-based assessment.

Methods: We compared current HIV detection practices to strategies of increasingly frequent routine HIV screening in Portuguese adults aged 18-69. We considered several subpopulations and geographic regions with varying levels of undetected HIV prevalence and incidence. Baseline inputs for the national case included undiagnosed HIV prevalence 0.16%, annual incidence 0.03%, mean population age 43 years, mean CD4 count at care initiation 292 cells/μL, 63% HIV test acceptance, 78% linkage to care, and HIV rapid test cost €6 under the proposed routine screening program. Outcomes included quality-adjusted survival, secondary HIV transmission, cost, and incremental cost-effectiveness.

Results: One-time national HIV screening increased HIV-infected survival from 164.09 quality-adjusted life months (QALMs) to 166.83 QALMs compared to current practice and had an incremental cost-effectiveness ratio (ICER) of €28,000 per quality-adjusted life year (QALY). Screening more frequently in higher-risk groups was cost-effective: for example screening annually in men who have sex with men or screening every three years in regions with higher incidence and prevalence produced ICERs of €21,000/QALY and €34,000/QALY, respectively.

Conclusions: One-time HIV screening in the Portuguese national population will increase survival and is cost-effective by international standards. More frequent screening in higher-risk regions and subpopulations is also justified. Given Portugal’s challenging economic priorities, we recommend prioritizing screening in higher-risk populations and geographic settings.

Citation: Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, et al. (2013) Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. PLoS ONE 8(12): e84173. doi:10.1371/journal.pone.0084173

Editor: Julian W. Tang, Alberta Provincial Laboratory for Public Health/ University of Alberta, Canada

Received August 27, 2013; Accepted November 20, 2013; Published December 18, 2013

Copyright: © 2013 Yazdanpanah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Sources of funding: Coordenação Nacional para Infecção VIH/SIDA, Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS), National Institute of Allergy and Infectious Diseases (R37 AI42006), National Institute of Mental Health (R01 MH065869), and the National Institute on Drug Abuse (R01 DA015612). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have read the journal's policy and have the following conflicts: Yazdan Yazdanpanah received travel grants, honoraria for presentations at workshops and consultancy honoraria from Abbott, Bristol-Myers Squibb, Gilead, Merck, Roche, Tibotec and Viiv Healthcare. Céu Mateus received money for grants, lectures, and expert testimony from Pfizer, AMGEN, and BIOPEN IDEC. All other authors declare that they have no conflicts of interest. All conflicts of interest have been disclosed in the manuscript. They do not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Introduction

By comparison to its European neighbors, Portugal bears an unusually severe HIV/AIDS burden. Its overall HIV/AIDS prevalence is 0.53% [1,2]. Incidence estimates range from 0.005% to 1.08% per year, depending on risk group, and Portugal has the second highest incidence rate in the European Union [3]. Late presentation is common: 30.7% of newly detected individuals have already advanced to AIDS [1].

The Portuguese National Health Service provides universal coverage for HIV testing and care. To encourage earlier detection of infection and initiation of HIV care, the Portuguese parliament recently adopted a resolution to expand routine, population-based HIV testing [4]. This policy mirrors the recommendations of the World Health Organization (WHO), the United States Centers for Disease Control and Prevention, and the French Haute Autorité de Santé [5–7].

Portugal faces numerous challenges in implementing this resolution. Most notable among these is the current economic crisis. Portugal’s Gross Domestic Product (GDP) per capita (€15,600) is among the lowest in Western Europe; in 2010, debt service accounted for 33% of the overall National Health Service budget [8]. In the face of these challenges, we sought to estimate the survival benefits, costs, and cost-effectiveness of alternative approaches to expanded HIV screening in Portugal.

Methods

Analytic Overview

We compared four strategies for HIV screening in Portuguese adults aged 18-69: 1) current practices of detection (notably non-routine, provider- or patient-initiated testing and presentation with opportunistic infections); versus current practices with the addition of 2) routine one-time screening; 3) routine screening every three years; and 4) routine annual screening. Given the geographic and demographic heterogeneity of the HIV/AIDS epidemic in Portugal, we also examined both regionally targeted screening and strategies focused on high-risk injection drug users (IDUs) and men who have sex with men (MSM).

We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model, a widely-published microsimulation of HIV disease, to forecast mean costs, life-expectancy, and quality-adjusted life expectancy in months (QALM) in both HIV-infected and HIV-uninfected individuals under each strategy [9–17]. These estimates take into account the impact of the intervention on secondary HIV infection.

Comparative value used the incremental cost-effectiveness ratios (ICERs), measured in both euros per year of life saved (€/YLS) and euros per quality-adjusted life-year saved (€/QALY). We applied the guidance of the WHO Commission on Macroeconomics and Health, which suggests that an intervention be labeled “cost-effective” in a given country if its ICER is less than three times the nation’s per capita GDP [18]. Since the Portuguese GDP is €15,600, programs delivering QALYs for less than €46,800 were deemed “cost-effective.”

Because our goal was to inform decision making at the level of the Portuguese National Health Service, we conducted our analyses from a modified societal perspective (excluding indirect costs), and discounted costs, life expectancy, and quality adjusted life expectancy at 5% per annum [19].

CEPAC Model

Disease Model. The Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model presents the natural history, treatment, and costs of HIV disease [9–17]. The model portrays disease progression as a sequence of monthly transitions between “health states.” Each simulated patient is followed monthly in the model until death [9–17]. The progression of HIV disease is determined by CD4 count, HIV RNA level, and history of opportunistic infection. Patients receiving ART have reduced HIV RNA, increased CD4 count, and protection from opportunistic infection (OIs) [20]. Morbidity is calculated as a single outcome measure that expresses survival while accounting for quality of life [10,19,21,22]. Further details on the structure of the CEPAC model have been reported elsewhere [9–13]. The CEPAC model has been used to estimate the cost-effectiveness of expanded screening programs in the United States, South Africa, and France [12–15,17].

Screening Module. While the Disease Model described above simulates the course of HIV illness for all infected individuals, only patients with detected HIV infection who are successfully linked to care are eligible for clinic visits, OI prophylaxis, and antiretroviral therapy [12–15,17,23]. The Screening Module uses information on HIV prevalence, incidence, testing behavior, and HIV test performance to determine eligibility for treatment and conveys that information to the Disease Model. Persons in the Screening Module may either be HIV-uninfected or HIV-infected; the infected population is further separated into prevalent cases (persons infected at the time of model initialization [t=0]) and incident cases (whose infection occurs after model initialization). HIV detection takes place via one of three mechanisms: a) “background HIV testing,” defined as Portugal’s current non-routine testing practice; b) presentation to clinic with an AIDS-defining OI; or c) expanded, routine HIV screening. HIV is currently diagnosed in Portugal via one of the first two detection mechanisms. (Further details on the Screening Module are provided in Appendix S1.)

Transmission Module. The Transmission Module uses deterministic methods to link the effects of expanded HIV screening and earlier treatment initiation to both community HIV RNA levels and the subsequent number and timing of secondary HIV infections. The Transmission Module maintains a running tally of both the size of the susceptible (i.e. uninfected) population and the aggregate level of HIV RNA among infected (treated and untreated) persons. These are then combined with both Portuguese incidence data and HIV

PLOS ONE | www.plosone.org 2 December 2013 | Volume 8 | Issue 12 | e84173
RNA-specific transmission rates from a variety of meta-analyses and modeling studies to estimate the number of new HIV transmissions in subsequent periods [1,24,25]. The Transmission Module permits us to estimate the impact of alternative HIV screening policies on transmissions from index cases to uninfected members of the population (i.e., first-order transmissions). By applying average discounted survival outcomes and costs from the CEPAC Disease Model to new infections, it also permits us to include the effects of secondary transmission in our cost-effectiveness estimates. (For further details on the Transmission Module, see Appendix S1.)

Input Data

Values for the key parameters used in our baseline assessment and plausible ranges we developed for the extensive sensitivity analyses are shown in Table 1. Further details on the protocols we used to assemble, develop, and validate these estimates are available in Appendix S1.

Cohort Sociodemographic Characteristics. The baseline characteristics of the simulated cohort represent the Portuguese population aged 18 to 69 years old. The national population had a mean age of 44 years and was 49% male [28]. The MSM population had a mean age of 35 years (range 17-79 years) [29]. The IDU population had a mean age of 31 years (range 18-49). The IDU population was 71% male [28].

Disease Progression and Mortality. Recognizing the limited availability of Portuguese data on HIV natural history, we developed estimates using a combination of national and international sources and then subject all estimates to extensive sensitivity analysis. Data from two French clinical cohorts were employed to estimate CD4-stratified OI incidence and HIV-related mortality rates [29]. National age- and gender-stratified mortality rates unrelated to HIV/AIDS were first obtained from Portuguese sources. These were further adjusted for MSM and IDUs using previously published age- and gender-stratified mortality ratios for these sub-populations [26,30].

Treatment. Simulated patients who were HIV diagnosed and effectively linked to care were assumed to receive CD4 count and HIV RNA measurements every four months [31]. In accordance with Portuguese national guidelines, patients who were HIV diagnosed and successfully linked to care received ART when their CD4 count was below 350 cells/μL or when they had a WHO Stage III or IV OI [31]. ART regimens were switched when patients were observed to have experienced virologic failure, defined as an HIV RNA rebound to pre-ART levels. Values for ART and OI prophylaxis efficacies were obtained from published randomized controlled trials (Table 1) [32–37]. Because these outcomes were derived from intention-to-treat analyses, we assumed that adherence to prophylaxis was comparable to the level of adherence observed in the clinical trials. The level of adherence to ART in clinical trials may be higher than in non-trial settings. As a result we may have overestimated ART effectiveness. However, lower efficacies, in particular for ART, were considered in the sensitivity analysis.

Costs and Quality of Life. Data on resource use for non-ART routine medical care and death were obtained from a survey of 5 Portuguese National Health System (NHS) hospitals [38]. ART regimen unit costs were the official prices paid by NHS hospitals and were obtained from the official Portuguese official tariffs. Unit costs for consultations were obtained from the Analytical Accounting of NHS Hospitals [40]. Quality of life values for given model events and health states were derived from published studies of health state utilities in HIV-infected patients [41,42]. All costs were converted to 2012 Euros [43].

HIV Prevalence and Incidence. Prevalence was derived using data from the National Institute for Health (INSA), the Portuguese agency responsible for completing compulsory data collection of HIV-positive diagnoses [1]. INSA reported a prevalence of 0.37% diagnosed cases in 2008. Applying a European report that 30% of all HIV cases are undiagnosed [2], we estimated a prevalence of undiagnosed HIV of 0.16% and an overall national prevalence of 0.53%. Prevalence data were obtained for twenty different country regions as well as for MSM and IDUs [1]. National and regional annual incidence rates for the national population and these sub populations were obtained from INSA and stratified by age by applying incidence rate ratios from a study of HIV incidence in the United States [1,44]. (The methods used to calculate risk group incidence are described in Appendix S1.)

Characteristics of “Background Testing”. In Portugal, HIV testing is performed on demand, and routinely proposed to pregnant women, patients with tuberculosis and sexually transmitted infections, and prisoners. Data from five large Portuguese hospitals, representing 38.1% of HIV patients in care in Portugal indicated that, for the year 2008, the median CD4 count for all patients initiating HIV care with current testing practices was 292 cells/μL (SD 282) [38]. Mean CD4 at presentation to care for MSM (347 cells/μL (SD 336)) and IDUs (269 cells/μL (SD 260)) was derived by applying ratios from a French study that examined screening rates among the French national population, MSM and IDUs [17].

To determine the delay from infection to initiation of HIV care for the national population, we ran simulations where we offered no routine HIV screening and varied the non-routine screening rate. When we set the non-routine screening rate to once every 66 months, the mean CD4 count at presentation to care was 293 cells/μL, which closely approximates Portuguese surveillance data. This delay suggests a 1.52% constant monthly probability of background HIV testing, diagnosis and linkage to care. We repeated the same analysis for MSM and IDUs and determined that background testing occurs once every 39 months among MSM and once every 90 months among IDUs.

To offer a conservative portrayal of the incremental benefits of expanded, routine HIV screening, we adopted a favorable view of background testing performance: 100% test sensitivity; 100% test specificity; and immediate linkage to care for 100% of detected cases. Doing so had the effect of understating the incremental benefits and cost-effectiveness of routine HIV testing, hence biasing the analysis against our own conclusions. Any retreat to a less favorable view of current
Table 1. Input Parameters for a Model of Routine HIV Screening in Portugal.

| Parameter                                                                 | Baseline Value | Range for Sensitivity Analyses | Source |
|--------------------------------------------------------------------------|----------------|--------------------------------|--------|
| **Cohort Characteristics**                                              |                |                                |        |
| Mean age (SD), years, national population                               | 43 (14)        | 38-48                          | [26]   |
| Mean age (SD), years, MSM population                                    | 35 (12)        |                                | [27]   |
| Mean age (SD), years, IDU population                                    | 31 (10)        |                                | [28]   |
| Men, % of patients, national population                                 | 49             |                                | [26]   |
| Men, % of patients, IDU population                                      | 71             |                                | [28]   |
| **Efficacy of ART (% patients with HIV RNA suppression at 24 weeks)**   |                |                                |        |
| 1st Line ART                                                            | 86             | 73-99                          | [32]   |
| 2nd Line ART                                                            | 73             | 62-84                          | [37]   |
| 3rd Line ART                                                            | 61             | 52-70                          | [37]   |
| 4th Line ART                                                            | 65             | 55-75                          | [33]   |
| 5th Line ART                                                            | 40             | 34-46                          | [35,36]|
| 6th Line ART                                                            | 15             | 13-17                          | [35]   |
| **Treatment costs, 2012 €**                                             |                |                                |        |
| 1st Line ART                                                            | 780            | 550-1,014                      | [39]   |
| 2nd Line ART                                                            | 995            | 697-1,294                      | [39]   |
| 3rd Line ART                                                            | 1,072          | 750-1,394                      | [39]   |
| 4th Line ART                                                            | 1,569          | 1,098-2,040                    | [39]   |
| 5th Line ART                                                            | 2,259          | 1,581-2,937                    | [39]   |
| 6th Line ART                                                            | 888            | 622-1,154                      | [39]   |
| **Prevalence of undiagnosed HIV, %**                                    |                |                                |        |
| National population                                                     | 0.16           | 0.03-0.30                      | [1,2]  |
| IDUs                                                                    | 6.69           |                                | [2.54] |
| MSM                                                                     | 3.34           |                                | [2.55] |
| **Annual incidence rate, %**                                            |                |                                |        |
| National population                                                     | 0.03           | 0.01-0.04                      | [1]    |
| IDUs                                                                    | 1.08           |                                | [38,56]|
| MSM                                                                     | 0.43           |                                | [38,56]|
| **Mean CD4 count (SD) at HIV care initiation in the “current practice” scenario, cells/μL** | | | |
| National population                                                     | 292 (282)      |                                | [38]   |
| IDUs                                                                    | 269 (260)      |                                | [38,56]|
| MSM                                                                     | 347 (336)      |                                | [38,56]|
| **Testing behavioral characteristics of proposed routine HIV screening program** | | | |
| Probability of test offer, %                                            | 80             |                                | Assumption |
| Probability of test acceptance, %                                       | 79             | 32-100*                        | [47]   |
| Probability of linkage to care, %                                       | 78             | 20-100                         | [48]   |
| **Costs associated with routine HIV screening program, 2012 €**          |                |                                |        |
| HIV test cost                                                           | 6              | 6-37                           | [49]   |
| Confirmatory test (blood draw, Western Blot)                            | 102            |                                | [49]   |
| Post-test counseling costs for HIV+ patients                             | 32             |                                | [49]   |
| **Secondary transmission rate for heterosexuals and IDUs stratified by plasma HIV RNA (copies/mL)/100 person-years** | | | |
| > 50,000                                                                | 9.0            | 3.9-21.1                       | [24]   |
| 10,000-49,999                                                           | 8.1            | 2.8-23.8                       | [24]   |
| 3,500-9,999                                                             | 4.2            | 0.8-20.7                       | [24]   |
| 400-3,499                                                               | 2.1            | 0.6-7.5                        | [24]   |
| <400                                                                    | 0.2            | 0.0-1.1                        | [24]   |
| **Secondary transmission rate for MSMs stratified by plasma HIV RNA (copies/mL)/100 person-years** | | | |
| > 50,000                                                                | 72.2           |                                | [24,25]|
| 10,000-49,999                                                           | 65.0           |                                | [24,25]|
| 3,500-9,999                                                             | 33.4           |                                | [24,25]|
| 400-3,499                                                               | 16.5           |                                | [24,25]|
| <400                                                                    | 1.6            |                                | [24,25]|

PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e84173
practice would only serve to strengthen the findings reported below [45,46].

**Characteristics of Routine Screening Program.** For routine HIV screening in all settings and risk groups, we used a test offer rate of 80%, a test acceptance rate of 79%, and a linkage to care rate of 78% [47,48]. Testing was performed using a rapid HIV test without pre-test counseling, at a cost of €6 [49]. Patients with a positive result returned for a physician consult, a blood draw and confirmatory Western blot, with a total cost of €102 [49]. This physician visit included post-test counseling and linkage to care. We varied these parameters widely in sensitivity analyses for all three groups.

**Secondary HIV Transmission.** For the national, regional and IDUs analyses, the estimated rate of HIV transmission ranged from 0.2/100 PY at HIV RNA levels <400 copies/mL to 9.0/100PY at HIV RNA levels >50,000 copies/mL. These values were derived from a meta-analysis of 11 studies that followed a total of 5,021 heterosexual couples with 461 observed HIV transmission events in eight countries [24]. For the MSM analysis, we assumed that transmission occurred at eight times the rate it does in the heterosexual population [25].

**Results**

**Base Case – National Program**

Under the “current practice” scenario, the discounted quality-adjusted life expectancy is 194.31 QALMs (undiscounted 464.86 QALMs) and the discounted per-person HIV-related costs are €630 for the national population (includes HIV-uninfected and HIV-infected people). In the HIV-infected population, the mean CD4 count at diagnosis is estimated at 293 cells/μL, and the discounted quality-adjusted life expectancy of HIV-infected persons is 164.09 QALMs (undiscounted 367.76 QALMs), (Table 2).

After the addition of a one-time routine HIV screen to current practice, the quality-adjusted life expectancy is 194.32 QALMs (undiscounted 464.90 QALMs), and the average discounted lifetime HIV-related costs are €680/person, for the general population. The addition of a one-time routine HIV screen increases mean CD4 count at diagnosis to 306 cells/μL, and the quality-adjusted life expectancy to 166.83 QALMs (undiscounted 373.36 QALMs). The ICER of one-time screening compared to current practice is €30,000/QALY if one does not account for secondary transmission and €28,000/QALY if one does account for secondary transmission. This suggests that one-time screening is cost-effective (ICER less than €46,800, or three times Portuguese GDP).

Screening patients every three years or annually further increases survival and costs. The ICERs for screening every three years are €50,000/QALY and €44,000/QALY, excluding and including secondary transmission, respectively. The ICER for annual screening is €65,000/QALY if secondary transmission is not considered and €59,000/QALY if it is considered. All further ICERs presented include the impact of secondary transmission.

**Regional Analysis**

Compared to current practice, the addition of a one-time, routine HIV screening is cost-effective in each of the 20 different regions of Portugal (Table 3), with ICERs ranging from €27,000 to €38,000 per QALY. In six regions (Açores, Madeira, Porto, Faro, Setúbal, and Lisboa), increasing the screening frequency to every three years is also cost-effective, with ICERs ranging from €34,000 to €43,000 per QALY. Annual screening is not cost-effective in any of the regions.

**Risk Group Analysis**

Among MSM, compared to current practice, not only one-time routine HIV-screening, but also annual screening is cost-effective (undiagnosed prevalence 3.34% and annual incidence 0.43%; ICER = €21,000/QALY). In IDUs, (undiagnosed prevalence 6.69%, annual incidence of 1.08%), all strategies are cost-effective, with ICERs ranging from €26,000 to €30,000 per QALY. Additional results from the risk group analysis are provided in Table 4.

**Additional Sensitivity Analyses**

In a series of one-way sensitivity analyses (Figure 1), we varied each of the key parameters across plausible ranges, while holding all other input values at baseline. The three parameters that caused the greatest change in the ICER for one-time screening were: linkage to care, the costs of ART, and HIV screening costs, but the ICER of one-time, routine, nationwide screening remained less than €46,800 (three times the Portuguese GDP of €15,600). (Additional one-way sensitivity analyses are reported in Appendix S1.)

We then examined the effects of varying these most influential parameters simultaneously. At the baseline testing cost of €6, one-time screening is cost-effective whenever linkage to care exceeds 20%; this persists across the range of ART costs we considered. However, when testing costs are increased to €37 and ART costs are held at their baseline value, one-time routine screening is cost-effective only at linkage to care rates greater than 40%. At current ART and HIV test costs, one-time screening is cost-effective for HIV prevalence levels greater than 0.1% (undiagnosed HIV prevalence 0.03%). When the test cost is increased to €37, one time testing is cost-effective at an overall HIV prevalence of 0.2%.
Table 2. Base Case: Routine HIV Screening in Portuguese National Population.

| Variable                        | Current Practice | One-Time Screening | Screening Every Three Years | Annual Screening |
|---------------------------------|------------------|--------------------|----------------------------|-----------------|
| **General population**          |                  |                    |                            |                 |
| Mean undiscounted life expectancy, LM | 465.14           | 465.19             | 465.24                     | 465.29          |
| Mean discounted life expectancy, LM | 194.40           | 194.42             | 194.44                     | 194.45          |
| Mean undiscounted quality-adjusted life expectancy, QALM | 464.86           | 464.90             | 464.96                     | 465.00          |
| Mean discounted quality-adjusted life expectancy, QALM | 194.31           | 194.32             | 194.34                     | 194.35          |
| Mean discounted lifetime costs per person, €\(^1\) | 630              | 680                | 740                         | 810             |
| **HIV-infected population**      |                  |                    |                            |                 |
| Mean CD4 at detection, all cases (cells/μL) | 293              | 306                | 353                         | 398             |
| Mean undiscounted life expectancy, LM\(^2\) | 407.84           | 414.29             | 422.78                      | 428.76          |
| Mean discounted life expectancy, LM\(^2\) | 177.98           | 181.05             | 183.25                      | 185.44          |
| Mean undiscounted quality-adjusted life expectancy, QALM\(^2\) | 367.76           | 373.36             | 381.42                      | 387.14          |
| Mean discounted quality-adjusted life expectancy, QALM\(^2\) | 164.09           | 166.83             | 168.93                      | 170.96          |
| Mean discounted lifetime costs per person, €\(^1\) | 91,410           | 97,610             | 103,740                     | 109,680         |
| Reduction in secondary cases over ten years | ---              | 4.9%               | 5.3%                        | 6.1%            |
| QALM associated with transmission, discounted | 70.00            | 70.01              | 70.02                       | 70.02           |
| Costs associated with transmission, discounted\(^3\) | 110              | 130                | 140                         | 150             |
| Incremental cost-effectiveness ratios, €/QALY\(^3\) | ---              | 30,000             | 50,000                      | 65,000          |
| Without secondary transmission\(^4\) | ---              | 28,000             | 44,000                      | 59,000          |
| With secondary transmission\(^5\) | ---              | 3,000              | 5,000                       | 6,000           |

\(^1\) Costs are rounded to the nearest €10.

\(^2\) Life-expectancy for HIV-infected represents the average life expectancy for all persons who have ever had HIV infection from the time of model entry.

\(^3\) ICERs are rounded to the nearest €1,000/QALY. The comparator strategy is always the next smallest, not dominated, alternative.

\(^4\) Incremental cost-effectiveness without secondary transmission = (cost per person in strategy 2 - cost per person in strategy 1)/ (QALMs per person in strategy 2 - QALMs per person in strategy 1)*12.

\(^5\) Incremental cost-effectiveness with secondary transmission = [(cost per person in strategy 2 + cost accrued per transmission in strategy 2) – (cost per person in strategy 1 + cost accrued per transmission in strategy 1)]/ (QALMs per person in strategy 2 + QALMs accrued per transmission in strategy 2) – (QALMs per person in strategy 1 + QALMs accrued per transmission in strategy 1)].

LM: life month; QALM: quality-adjusted life month; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio
doi: 10.1371/journal.pone.0084173.t002

0.3% (undiagnosed HIV prevalence 0.09%) or greater. (Further sensitivity analyses are reported in Appendix S1.)

Impact of Expanded Screening on Secondary HIV Transmission

The addition of a national, one-time screen reduces the number of secondary transmissions by 4.9% over ten years. Screening every three years further reduces the number of secondary cases by 5.3%, while screening annually reduces the number of secondary cases over ten years by an additional 6.1% (see Appendix S1). When these HIV transmission effects are taken into account, screening every 3 years is cost-effective in six regions— including the four with the highest undiagnosed HIV prevalence and incidence (Porto, Faro, Setúbal and Lisboa, Table 3).

Discussion

One-time, routine, voluntary HIV screening in the Portuguese general population meets widely cited international standards of cost-effectiveness. More frequent screening among high-risk populations and in the four geographic regions with the highest HIV prevalence/incidence is also cost-effective. Among both MSM and IDUs, the returns to increased investment in screening are virtually proportional to incidence, suggesting that screening in these populations as often as yearly is warranted. Previous studies have demonstrated the cost-effectiveness of expanded testing in the specific context of middle-income countries (South Africa) and high-income countries (France, US) [12,13,17]. In the former case, cost-effectiveness was largely related to the low cost of ART and the very high burden of disease; in the latter case, results were driven large measure by national income and the consequent willingness to pay for relatively small health gains. Portugal represents an intermediate case – a nation which, like many others, benefits from neither low ART prices nor very high GDP but which still bears the burden of a relatively high HIV prevalence and incidence. It is instructive, therefore, to find that a one-time, routine, voluntary HIV screening in the Portuguese general population still meets international standards of cost-effectiveness.

There is no universally accepted definition for a “cost-effective” ICER. The WHO offers general guidance and states that an ICER that is less than one time the per capita GDP for a specific country is “very cost-effective” in that context, and an ICER that is less than three times the per capita GDP is “cost-effective” [50]. These thresholds have been widely used to take
into account national ability to pay. In Portugal, this sets a limit for an ICER to be considered cost-effective at €46,800. Anecdotal evidence suggests that the Portuguese National Authority of Medicines (Infarmed) adopts an informal threshold of €30,000/QALY in determining whether a given pharmaceutical intervention is cost-effective. This threshold is inspired by the United Kingdom National Institute for Health and Clinical Excellence (NIHCE) guidelines [51]. Our ICER estimate for a national one-time screening is just under that threshold. Thus, one-time, routine, voluntary HIV screening in the general population meets both widely cited international standards and informally understood standards of cost-effectiveness in Portugal. However, given the challenges of national implementation, as well as constrained resources, it may prove both practical and expedient to begin by initiating routine HIV screening first among IDUs and MSM and in the four high-prevalence regions, where the ICERs are unequivocally favorable, both by formal and informal standards. At €28,000/QALY, the cost-effectiveness ratio for one-time, nation-wide screening in Portugal stands in contrast to higher ICERs, which we have previously obtained using similar methods and national data from both France (€60,400/QALY) and the United States (€67,400/QALY) [12,13,17]. These differences are explained by Portugal’s higher levels of undiagnosed HIV prevalence, higher HIV incidence, lower mean CD4 counts at presentation to care under current practices of HIV detection, and lower costs of HIV screening.

While instructive to note the differences between this analysis and previous findings, it is also useful to highlight important qualitative similarities. First, we once again find that

| Region       | Undiagnosed HIV Prevalence, % | Annual HIV Incidence, (/100 PY) | ICER (€/QALY) Without accounting for secondary transmission | ICER (€/QALY) Accounting for secondary transmission |
|--------------|-------------------------------|--------------------------------|-------------------------------------------------------------|-----------------------------------------------------|
|              |                               |                                | One-Time Screening                                          | Screening Every Three Years                          |
|              |                               |                                | ICER (€/QALY)                                               | ICER (€/QALY)                                        |
|              |                               |                                | Without domination                                          | Accounting for secondary transmission               |
|              |                               |                                | One-Time Screening                                          | Screening Every Three Years                          |
| Guarda       | 0.03                          | 0.005                           | 40,000                                                     | 36,000                                              |
| Viana do Castelo | 0.04                         | 0.008                           | 36,000                                                     | 33,000                                              |
| Vila Real    | 0.05                          | 0.007                           | 34,000                                                     | 31,000                                              |
| Viseu        | 0.05                          | 0.009                           | 34,000                                                     | 31,000                                              |
| Castelo Branco | 0.05                         | 0.011                           | 31,000                                                     | 29,000                                              |
| Bragança     | 0.06                          | 0.008                           | 33,000                                                     | 31,000                                              |
| Braga        | 0.06                          | 0.009                           | 35,000                                                     | 31,000                                              |
| Aveiro       | 0.06                          | 0.017                           | 33,000                                                     | 30,000                                              |
| Acores       | 0.06                          | 0.021                           | 36,000                                                     | 31,000                                              |
| Portalegre   | 0.07                          | 0.004                           | 34,000                                                     | 30,000                                              |
| Évora        | 0.07                          | 0.005                           | 30,000                                                     | 30,000                                              |
| Coimbra      | 0.08                          | 0.014                           | 31,000                                                     | 29,000                                              |
| Beja         | 0.09                          | 0.002                           | 34,000                                                     | 38,000                                              |
| Leiria       | 0.09                          | 0.015                           | 34,000                                                     | 31,000                                              |
| Santarém     | 0.09                          | 0.017                           | 31,000                                                     | 29,000                                              |
| Madeira      | 0.09                          | 0.023                           | 33,000                                                     | 30,000                                              |
| Porto        | 0.19                          | 0.031                           | 30,000                                                     | 28,000                                              |
| Faro         | 0.21                          | 0.035                           | 29,000                                                     | 27,000                                              |
| Setúbal      | 0.26                          | 0.030                           | 32,000                                                     | 30,000                                              |
| Lisboa       | 0.29                          | 0.046                           | 28,000                                                     | 27,000                                              |

1. ICERs are rounded to the nearest €1,000/QALY. The comparator strategy is always the next smallest, not dominated, alternative.
2. Dominated: less effective and more costly than some combination of alternative strategies, for the same region.
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year
doi: 10.1371/journal.pone.0084173.t003
Table 4. HIV Screening in High Risk Groups in Portugal.

| Variable                                      | Current Practice | One-Time Screening | Screening Every Three Years | Annual Screening |
|-----------------------------------------------|------------------|--------------------|-----------------------------|------------------|
| **Men who have sex with men (undiagnosed HIV prevalence = 3.34%, annual HIV incidence = 0.43%)** |                  |                    |                             |                  |
| General population                            |                  |                    |                             |                  |
| Mean undiscounted life expectancy, LM         | 510.33           | 511.00             | 511.71                      | 512.26           |
| Mean discounted life expectancy, LM           | 202.94           | 203.28             | 203.45                      | 203.67           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 504.13           | 504.73             | 505.41                      | 505.92           |
| Mean discounted quality-adjusted life expectancy, QALM | 200.82           | 201.12             | 201.28                      | 201.49           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 14,830           | 15,500             | 16,060                      | 16,650           |
| **HIV-infected population**                   |                  |                    |                             |                  |
| Mean undiscounted life expectancy, LM         | 426.07           | 430.72             | 435.56                      | 439.58           |
| Mean undiscounted life expectancy, LM         | 183.40           | 185.77             | 187.01                      | 188.52           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 382.52           | 386.64             | 391.23                      | 395.05           |
| Mean discounted quality-adjusted life expectancy, QALM | 168.49           | 170.59             | 171.76                      | 173.20           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 104.170          | 109.030            | 112.710                     | 116.770          |
| Mean undiscounted quality-adjusted life expectancy, QALM | 23,110           | 25,490             | 25,630                      | 26,280           |
| **Incremental cost-effectiveness ratios, €/QALY** |                  |                    |                             |                  |
| Without secondary transmission                | ---              | 26,000             | Dominated                   | 37,000           |
| With secondary transmission                   | ---              | Dominated          | Dominated                   | 21,000           |
| **Injection drug users (undiagnosed HIV prevalence = 6.69%, annual HIV incidence = 1.08%)** |                  |                    |                             |                  |
| General population                            |                  |                    |                             |                  |
| Mean undiscounted life expectancy, LM         | 356.82           | 358.52             | 361.41                      | 363.31           |
| Mean undiscounted life expectancy, LM         | 169.17           | 170.08             | 170.95                      | 171.66           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 346.70           | 348.23             | 350.94                      | 352.73           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 165.14           | 165.96             | 166.77                      | 167.44           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 24,960           | 26,840             | 29,280                      | 31,370           |
| **HIV-infected population**                   |                  |                    |                             |                  |
| Mean undiscounted life expectancy, LM         | 324.55           | 330.21             | 339.86                      | 346.27           |
| Mean undiscounted life expectancy, LM         | 160.00           | 163.07             | 165.98                      | 168.35           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 290.69           | 295.74             | 304.80                      | 310.85           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 146.49           | 149.26             | 151.99                      | 154.23           |
| Mean undiscounted quality-adjusted life expectancy, QALM | 83,730           | 89,910             | 96,030                      | 104,960          |
| Mean undiscounted quality-adjusted life expectancy, QALM | ---              | 4.64               | 6.72                        | 7.46             |
| Mean undiscounted quality-adjusted life expectancy, QALM | 81.65            | 82.09              | 82.32                       | 82.56            |
| Mean undiscounted quality-adjusted life expectancy, QALM | 4,470            | 5,360              | 5,380                       | 5,560            |
| **Incremental cost-effectiveness ratios, €/QALY** |                  |                    |                             |                  |
| Without secondary transmission                | ---              | 28,000             | 36,000                      | 38,000           |
| With secondary transmission                   | ---              | 28,000             | 28,000                      | 30,000           |

1 Costs are rounded to the nearest €10.
2 Life-expectancy for HIV-infected represents the average life expectancy for all persons who have ever had HIV infection from the time of model entry.
3 ICERs are rounded to the nearest €1,000/QALY. The comparator strategy is always the next smallest, not dominated, alternative.
4 Incremental cost-effectiveness without secondary transmission = (cost per person in strategy 2 - cost per person in strategy 1)/[(QALMs per person in strategy 2 - QALMs per person in strategy 1)*12].
5 Incremental cost-effectiveness with secondary transmission = ([cost per person in strategy 2 + cost accrued per transmission in strategy 2] – [cost per person in strategy 1 + cost accrued per transmission in strategy 1])/(QALMs per person in strategy 2 + QALMs accrued per transmission in strategy 2) – (QALMs per person in strategy 1 + QALMs accrued per transmission in strategy 1).
6 Dominated: higher cost-effectiveness ratio compared to preceding strategy.

LM: life month; QALM: quality-adjusted life month; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.

doi: 10.1371/journal.pone.0084173.t004

Population-wide routine HIV screening is easily justified as a comparatively attractive use of scarce health resources. Second, we see that the cost-effectiveness of HIV screening is surprisingly insensitive to both the prevalence of undetected HIV in the target population and the cost of the HIV test. At current ART costs, only at undetected HIV prevalence levels less than or equal to 0.09% (overall prevalence of 0.3%) do the costs of counseling and testing itself begin to affect decision.
Finally, we once again find that secondary transmission effects – while notable when measured on a population-wide basis over a long time horizon – exert minimal influence on the cost-effectiveness ratio [12].

This study has several limitations. First, the results are based on a mathematical model that estimates long-term consequences of different strategies based on data from multiple sources, some of which by necessity are not Portuguese. For example, the proportion of undiagnosed HIV cases (30%) is based on estimates for Europe and is not specific to Portugal [2]. Moreover, in the absence of available data in our regional population analysis, we assumed that the background testing rate is the same for all regions. The sensitivity analyses on these and other input parameters demonstrate that the results are robust to variations in these assumptions. However, while these sensitivity analyses were conducted to manage the uncertainties in our input data assumptions, a more complete exploration would have included a probabilistic sensitivity analysis (PSA), providing a cost-effectiveness acceptability curve showing the probability of cost-effectiveness of one-time screening against varying willingness-to-pay threshold values. Recognizing the difficulties of conducting PSA alongside a Monte Carlo microsimulation such as ours, we have adhered as closely as possible to the guidance of both the US Panel on Cost-effectiveness in Health and Medicine and the joint SMDM- ISPOR Task Force on Good Modeling Practice, both of which endorse the use of deterministic methods—as the one we have performed—to manage uncertainty [19,45,46]. Second, although we did account for the effect of HIV RNA levels on transmission, the population-level data we used for the heterosexual and IDU groups were based on a meta-analysis of studies of heterosexual, serodiscordant couples [24]. While we applied a multiplier to do this for our MSM analysis, this multiplier came from a model-based rather than a cohort study [25]. Furthermore, we only simulated first-order transmissions rather than transmission effects – while notable when measured on a population-wide basis over a long time horizon – exert minimal influence on the cost-effectiveness ratio [12].

Figure 1. One-Way Sensitivity Analysis on Cost-Effectiveness of One-Time, Routine, National HIV Screening in Portugal. The width of the bar is the variation in the incremental cost-effectiveness ratio associated with alternative parameter values for that input, when secondary transmissions are taken into account. The numbers in parentheses next to each parameter on the y-axis indicate the base case value, and the numbers in brackets indicate the lower and upper-bounds used in the sensitivity analyses. QALY: quality-adjusted life year. ICER: incremental cost-effectiveness ratio.
doi: 10.1371/journal.pone.0084173.g001
than use a fully dynamic HIV transmission model. Therefore, we may have under-represented the rates of infection and, therefore, the cost-effectiveness of HIV testing in high-risk populations. However, varying the probabilities of HIV transmission widely in sensitivity analyses produced no change in the cost-effectiveness of one-time routine screening. Finally, while we project that routine HIV testing will be cost-effective, this does not imply that it will necessarily be affordable; budget impact analysis will be a useful next step for budget planning [53].

In summary, we find that one-time routine HIV screening of the national population is a cost-effective intervention for Portugal. More frequent screening in higher-risk regions and sub-populations is also justified on both clinical and cost-effectiveness grounds. In light of Portugal’s current economic challenges, focusing on screening higher-risk populations and geographic settings should be a priority.

References

1. Departamento de doenças infecciosas, unidade de referência e vigilância epidemiológica, núcleo de vigilância laboratorial de doenças infecciosas (2012) Programa Nacional para a; Infeção VIH/SIDA. Infeção VIH/SIDA: A Situação em Portugal a 31 de Dezembro de 2011. Lisbon: Instituto Nacional de Saúde.

2. Hamers FF, Phillips AN (2008) Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med 9: 6-12. doi:10.1111/j.1469-1493.2008.00584.x. PubMed: 18557683.

3. OECD (2011). Health at a Glance 2011: OECD Indicators. OECD Publishing. Available: http://dx.doi.org/10.1787/health_glance-2011-en. Accessed 4 June 2013

4. Assembleia da República (2011) Resolução da assembleia da República nº161/2011. DR n.º 249, Série I de 2011-12-29. Available: http://dre.pt/pdf1sdip/2011/12/24900/0546305464.pdf. Accessed 24 May 2013

5. HAS (Haute Autorité de Santé) (2009). Dépistage de l’infection par le VIH en France: stratégies et dispositif de dépistage. Available: http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-10/synthese_depistage_viol_volet_2_vfr_2009-10-21_16-48-3_460.pdf. Accessed 20 May 2013

6. Bramson B, Handsfield H, Lampe M, Janssen R, Taylor A et al. (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. Morb and Mortal Weekly Report 55: 1-17.

7. Scaling up HIV testing and counselling in the WHO European Region as an essential component of efforts to achieve universal access to HIV prevention, treatment, care and support: policy framework. World Health Organization (2010) Available: http://www.euro.who.int/_data/assets/pdf_file/0007/85489/ES93715.pdf. Accessed 25 March 2013

8. Eurostat Database.Available: http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database. Accessed 15 May 2013

9. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA et al. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21: S117-S128. doi:10.1097/QAD.0b013e32832b7dca. PubMed: 17620747.

10. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-831. doi:10.1056/NEJM200103313441108. PubMed: 11481169.

11. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglatet X et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d’Ivoire. N Engl J Med 355: 1141-1153. doi:10.1056/NEJMoa060247. PubMed: 16971720.

12. Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavge LM et al. (2006) Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 145: 797-806. doi:10.7326/0003-4819-145-11-200612050-00004. PubMed: 17146094.

13. Peltier AD, Weinstein MC, Kimmel AD, Seage GR, Losina E et al. (2005) Expanded screening for HIV in the United States—a analysis of cost-effectiveness. N Engl J Med 352: 586-595. doi:10.1056/NEJMsai030286. PubMed: 15703423.

14. Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA et al. (2010) Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 51: 392-400. doi:10.1086/551350. PubMed: 20617921.

15. Walensky RP, Wood R, Fofana MD, Martinson NA, Losina E et al. (2011) The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 56: 26-35. doi:10.7326/0003-4819-56-1-201009220-00003. PubMed: 21598674.

16. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E et al. (2008) Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 197: 1324-1332. doi:10.1086/587184. PubMed: 18424454.

17. Yazdanpanah Y, Sloan CE, Charlos-Ou C, Le Vu S, Semaille C et al. (2010) Routine HIV screening in France: clinical impact and cost-effectiveness. PLOS ONE 5: e13132. doi:10.1371/journal.pone.0013132. PubMed: 20976112.

18. Tan-Torres Edejer T, Baltussen R, Adam T, Hububessy R, Acharya A et al. (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.

19. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost effectiveness in health and medicine. New York: Oxford University Press.

20. Cole SR, Heman MA, Robins JM, Anastas K, Chmiel J et al. (2003) Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiology 158: 679-694. doi:10.1093/aje/kwg206.

21. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD et al. (2001) Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 134: 440-450. doi:10.7326/0003-4819-134-6-200103300-00008. PubMed: 11255519.

22. Yazdanpanah Y, Goldie SJ, Paltiel AD, Losina E, Coudeville L et al. (2003) Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis 36: 86-96. doi:10.1086/344902. PubMed: 12491207.

23. Walensky RP, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E et al. (2005) Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med 118: 292-300. doi:10.1016/j.amjmed.2004.07.055. PubMed: 15745728.

24. Attila S, Egger M, Mülner M, Zwahlen M, Low N (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404. doi:10.1097/QAD.0b013e32832b7dca. PubMed: 19381076.

25. McCormick AW, Walensky RP, Lipitch M, Losina E, Hsu H et al. (2007) The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 44: 1115-1122. doi:10.1086/512861. PubMed: 17366461.

26. Portuguese National Institute of Statistics (2011) Portuguese statistical data for 2009-2011. Available: http://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_base_dados. Accessed 16 June 2013

27. Frange P, Meyer L, Deveaux C, Tran L, Goujard C et al. (2012) Recent HIV-1 infection contributes to the viral diffusion over the French territory

Supporting Information

Appendix S1. Technical Appendix. (DOCX)

Author Contributions

Conceived and designed the experiments: YY J. Perelman KAF ADP. Performed the experiments: YY MAD MR JEP ELR ADP. Analyzed the data: YY J. Perelman MAD ELR RPW KAF ADP. Wrote the manuscript: YY J. Perelman MAD ELR ADP. Assisted with interpretation and revision of the report: JA HB CM J. Pereira KM MR JEP EL RPW FN KAF.
with a recent increasing frequency. PLOS ONE 7: e31695. doi:10.1371/journal.pone.0031695. PubMed: 22348121.
28. Esteves A, Parreira R, Piedade J, Venenno T, Franco M et al. (2003) Spreading of HIV-1 subtype G and env/BagG recombinant strains among injecting drug users in Lisbon, Portugal. AIDS Res Hum Retroviruses 19: 511-517. doi:10.1089/088922203766774586. PubMed: 12892060.
29. Yazdanpanah Y, Chêne G, Losina E, Goldie SJ, Merchadou LD et al. (2001) Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 30: 864-871. doi:10.1093/ije/30.4.864. PubMed: 11511618.
30. Seage GR, Holte SE, Metzger D, Koblin BA, Gross M et al. (2001) Are US populations appropriate for trials of human immunodeficiency virus vaccines? The HIVNET vaccine preparedness study. Am J Epidemiology 153: 619-627. doi:10.1093/aje/153.7.619.
31. Coordenación Nacional para la infecció de VIH/SIDA (2009). Recomendaciones portuguesas para o tratamiento da infección; VIH-SIDa. Available: http://www.aidsportugal.com/Modules/WebC_Docs/GetDocument.aspx?DocumentId=82. Accessed 20 July 2013
32. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260. doi:10.1056/NEJMoa061871. PubMed: 16421366.
33. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1281-1289. doi:10.1016/S0140-6736(07)60597-2. PubMed: 17443401.
34. Johnson M, Grinsztejn B, Rodrigues C, Cocco J, DeJesus E et al. (2005) Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing triple virological failures. AIDS 19: 685-694. doi:10.1097/01.aids.0000216371.76689.63. PubMed: 16280694.
35. Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K et al. (2005) Durable efficacy of efavirenz over 48 weeks in heavily treatment-experienced patients infected with CCR5-tropic HIV-1: 24-104bLB. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA.
36. Esteves A, Scharfstein JA, Seage GR, Losina E, Goldie SJ et al. (1998) A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 18: S93-S105. doi:10.1177/0272989X9801800211. PubMed: 9566470.
37. Rachakuman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J et al. (2002) Comparison of health state utilities using community and patient preference weights derived from a survey of HIV/AIDS Med Decis Making 22: 27-38. doi:10.1177/0272989X220262892. PubMed: 11833663.
38. International Monetary Fund (2013). World Economic Outlook Database. Available: http://www.imf.org/external/pubs/ft/weo/2004/01/data/index.htm. Accessed 23 April 2013
39. Prejean J, Song R, Hernandez A, Ziebrell R, Green T et al. (2011) Estimated HIV incidence in the United States, 2006–2009. PLOS ONE 6: e17502. doi:10.1371/journal.pone.0017502. PubMed: 21826193.
40. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ et al. (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 15: 835-842. doi:10.1016/j.jval.2012.04.014. PubMed: 22999133.
41. Rodrigues J, Marques P, Pimentel L (2011) Testes reativos CAD VIH/SIDA Porto. Poster session presented at VIH Portugal, Lisbon, Portugal.
42. Ministério da Saúde (2009) Portaria nº 132/2009. Diário da República, 1. série - N.º 21.
43. World Health Organization (2009) CHOosing interventions that are cost-effective (WHO-CHOICE): Cost-effectiveness thresholds. Geneva: World Health Organization. Available: http://www.who.int/choice/en/. Accessed 23 June 2013
44. McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26: 733-744. doi:10.2165/00019053-20082609-0-00004. PubMed: 18767894.
45. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352: 570-585. doi:10.1056/NEJMsa042657. PubMed: 15703422.
46. Garattini L, van de Vooren K (2011) Budget impact analysis in economic evaluation: a proposal for a clearer definition. Eur J Health Econ 12: 499-502. doi:10.1007/s10198-011-0348-5. PubMed: 21814375.
47. Mathers BM, Degenhardt L, Phillips B, Wiesing L, Hickman M et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 373: 1733-1745. doi:10.1016/S0140-6736(08)61311-2. PubMed: 18179685.
48. The European MSM internet survey (EMIS) community report 1.eu. Available: http://www.emis-project.eu/sites/default/files/public/publications/EMIS_2010_CommunityReport1_English_0.pdf. Accessed 12 May 2013.
49. Yazdanpanah Y, Sloan CE, Charlos-Ou C, Le Vu S, Costagliola D, et al. (2010) Routine HIV screening in France: clinical impact and cost-effectiveness: Appendix S1. PLOS ONE 5: e13132.